Takara Bio Of Japan, University Join To Make Protein-Based Cancer Drug
This article was originally published in PharmAsia News
Japan's Takara Bio and Kyoto Prefectural University of Medicine plan to develop an immunotherapy drug to treat cancer by relying on a single protein. Researchers at the institutions plan to use the RetroNectin recombinant protein. The researchers believe the treatment could extend the life of lymph cells in cancer patients. No estimation was provided about sales expectations or forecast of marketing approval. (Click here for more - a subscription may be required
You may also be interested in...
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.